pharmaphorum

OCTOBER 19, 2022

The dark genome – a loose term that covers non-coding regions of the genome that are capable of regulating the expression of genes, previously rather inaccurately referred to as junk DNA – is increasingly being explored by biopharma companies for new drug targets.

Genome 59

Genome Genomics Gene Gene Expression 59

Roots Analysis

AUGUST 31, 2023

Further, the transcription factors contain two molecular domains, the DNA binding domain and the activation domain. Moreover, some transcription factors contain additional domains, such as ligand binding domain in order to interact with chemical signals.

Gene 40

Gene Gene Therapy Gene Expression Regulation 40

Pharmaceutical Technology

JANUARY 24, 2023

The investigational adeno-associated virus (AAV) gene therapy candidate NGN-401 is claimed to be the first to deliver the full-length human MECP2 gene using the company’s Expression Attenuation via Construct Tuning (EXACT) gene regulation technology.

Gene Therapy 208

Gene Therapy Gene Gene Expression Regulation 208

XTalks

MAY 4, 2021

These modifications regulate gene expression without changing the sequence or structure of DNA. We can do this for multiple genes at the same time without any DNA damage, and in a way that can be reversed. It’s a great tool for controlling gene expression.”. pyogenes dCas9.

DNA 98

DNA Gene Gene Silencing Genome 98

XTalks

MAY 4, 2021

These modifications regulate gene expression without altering the sequence or structure of DNA. We can do this for multiple genes at the same time without any DNA damage, and in a way that can be reversed. It’s a great tool for controlling gene expression.”. pyogenes dCas9.

DNA 52

DNA Gene Gene Silencing Genome 52

Drug Discovery World

JULY 15, 2022

The new sequences contain largely highly repetitive DNA structures such as centromeres, telomeres, acrocentric genomic regions, where massive arrays of tandem repeats predominate, and heterochromatin. In turn, this will aid our understanding of the cells capacity to silence harmful DNA elements or prevent inappropriate gene expression.

Genome 52

Genome Genomics DNA Containment 52

The Pharma Data

NOVEMBER 9, 2020

Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities.

Trials 52

Trials Production Sales Manufacturing 52